Canakinumab  	Canakinumab  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
Patient  	Patient  	 NNP	O
With  	With  	 IN	O
Difficult-to-Treat  	Difficult-to-Treat  	 NNP	B-NP
Gouty  	Gouty  	 NNP	O
Arthritis 	Arthritis 	 NNP	O
:  	:  	 :	O
Review  	Review  	 NNP	O
of  	of  	 IN	O
the  	the  	 DT	O
Clinical  	Clinical  	 NNP	B-NP
Evidence  	Evidence  	 NNP	I-NP
Many  	Many  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
gouty  	gouty  	 JJ	O
arthritis  	arthritis  	 NN	B-NP
experience  	experience  	 NN	I-NP
frequent  	frequent  	 JJ	O
flares  	flares  	 NN	O
and  	and  	 CC	O
have  	have  	 VB	O
comorbidities  	comorbidities  	 NNS	B-NP
that  	that  	 WDT	O
may  	may  	 MD	O
limit  	limit  	 VB	O
their  	their  	 PRP$	O
anti-inflammatory  	anti-inflammatory  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
options  	options  	 NNS	I-NP
for  	for  	 IN	O
acute  	acute  	 JJ	O
flare  	flare  	 JJ	O
management 	management 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
contraindications  	contraindications  	 VBG	O
to  	to  	 TO	O
both  	both  	 DT	O
NSAIDs  	NSAIDs  	 JJ	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
colchicine 	colchicine 	 NN	B-NP
,  	,  	 ,	O
treatment  	treatment  	 NN	B-NP
options  	options  	 NNS	I-NP
are  	are  	 VBP	O
particularly  	particularly  	 RB	O
limited 	limited 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
there  	there  	 EX	O
is  	is  	 VBZ	O
an  	an  	 DT	O
unmet  	unmet  	 JJ	B-NP
medical  	medical  	 JJ	I-NP
need  	need  	 NN	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
subgroup  	subgroup  	 NN	B-NP
of  	of  	 IN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Two  	Two  	 CD	O
phase  	phase  	 CD	O
3  	3  	 CD	O
studies  	studies  	 NNS	O
and  	and  	 CC	O
their  	their  	 PRP$	O
extensions  	extensions  	 NNS	O
have  	have  	 VBP	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
a  	a  	 DT	O
single  	single  	 JJ	O
dose  	dose  	 NN	O
of  	of  	 IN	O
canakinumab  	canakinumab  	 NN	B-NP
during  	during  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	O
flare  	flare  	 NN	O
provided  	provided  	 VBD	O
rapid  	rapid  	 JJ	O
and  	and  	 CC	O
effective  	effective  	 JJ	O
pain  	pain  	 NN	B-NP
relief  	relief  	 NN	I-NP
and  	and  	 CC	O
prolonged  	prolonged  	 JJ	O
suppression  	suppression  	 NN	O
of  	of  	 IN	O
flares  	flares  	 NN	O
and  	and  	 CC	O
inflammation  	inflammation  	 NN	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
history  	history  	 NN	O
of  	of  	 IN	O
frequent  	frequent  	 JJ	O
flares  	flares  	 NN	O
and  	and  	 CC	O
contraindicated  	contraindicated  	 NN	O
for 	for 	 IN	O
,  	,  	 ,	O
intolerant  	intolerant  	 VBG	O
of 	of 	 IN	O
,  	,  	 ,	O
or  	or  	 CC	O
unresponsive  	unresponsive  	 JJ	O
to  	to  	 TO	O
NSAIDs  	NSAIDs  	 JJ	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
colchicine 	colchicine 	 NN	B-NP
.  	.  	 .	O
Canakinumab  	Canakinumab  	 NNP	B-NP
was  	was  	 VBD	O
consistently  	consistently  	 RB	O
superior  	superior  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
active  	active  	 JJ	O
comparator  	comparator  	 JJ	B-NP
triamcinolone  	triamcinolone  	 JJ	I-NP
acetonide  	acetonide  	 NN	I-NP
and  	and  	 CC	O
was  	was  	 VBD	O
generally  	generally  	 RB	O
well  	well  	 RB	O
tolerated  	tolerated  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
patient  	patient  	 JJ	O
population  	population  	 NN	O
with  	with  	 IN	O
a  	a  	 DT	O
high  	high  	 JJ	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
multiple  	multiple  	 JJ	O
medical  	medical  	 JJ	B-NP
comorbidities 	comorbidities 	 NN	I-NP
.  	.  	 .	O
Canakinumab  	Canakinumab  	 NNP	B-NP
should  	should  	 MD	O
therefore  	therefore  	 RB	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
treatment  	treatment  	 NN	B-NP
option  	option  	 NN	I-NP
in  	in  	 IN	O
a  	a  	 DT	O
target  	target  	 NN	B-NP
population  	population  	 NN	I-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
frequent  	frequent  	 JJ	O
gouty  	gouty  	 JJ	O
arthritis  	arthritis  	 NN	B-NP
attacks  	attacks  	 NNS	I-NP
who  	who  	 WP	O
are  	are  	 VBP	O
unable  	unable  	 JJ	O
to  	to  	 TO	O
use  	use  	 VB	O
NSAIDs  	NSAIDs  	 JJ	O
and  	and  	 CC	O
colchicine  	colchicine  	 NNS	B-NP
and  	and  	 CC	O
in  	in  	 IN	O
whom  	whom  	 WP	O
frequent  	frequent  	 JJ	O
use  	use  	 NN	O
of  	of  	 IN	O
corticosteroids  	corticosteroids  	 NN	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
considered  	considered  	 VBN	O
appropriate 	appropriate 	 JJ	O
.  	.  	 .	O
